aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST

Rhea-AI Summary

aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company, is set to report its third quarter 2020 financial results and provide a corporate update on November 12, 2020, after market close. The company is focused on the discovery and development of innovative medicines utilizing novel biological pathways, particularly through its lead product candidate, ATYR1923, aimed at treating inflammatory lung diseases. A conference call and webcast will take place on the same day at 5:00 p.m. EST.

Positive

• The upcoming financial results report may provide insights into company performance and strategic direction.
• Focus on innovative biotherapeutics leveraging novel biological pathways shows potential for future growth.

Negative

• None.

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2020 financial results and provide a corporate update after the market close on Thursday, November 12, 2020.

Conference Call and Webcast Details:
Thursday, November 12th @ 5:00 p.m. EST / 2:00 p.m. PST
Domestic: 844-358-9116
International: 209-905-5951
Conference ID: 4549288
Webcast: http://investors.atyrpharma.com/events-and-webcasts

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
aTyr Pharma
adunston@atyrpharma.com

FAQ

When will aTyr Pharma report its third quarter 2020 financial results?

aTyr Pharma will report its third quarter 2020 financial results on November 12, 2020, after market close.

What is the focus of aTyr Pharma's research and development?

aTyr Pharma's research and development is centered on innovative medicines based on novel biological pathways, specifically extracellular functionality and signaling pathways of tRNA synthetases.

What is ATYR1923?

ATYR1923 is a clinical-stage product candidate from aTyr Pharma designed to down-regulate immune engagement in inflammatory lung diseases.

What are the details for the conference call and webcast?

The conference call and webcast will occur on November 12, 2020, at 5:00 p.m. EST. The domestic call number is 844-358-9116, and the international call number is 209-905-5951.